Guidance
Update information
May 2017: Recommendation 1.5.12 was amended to add a link to NICE's technology appraisal guidance on nintedanib for the treatment of idiopathic pulmonary fibrosis. Two outdated recommendations for research were removed.
Minor changes since publication
September 2024: We added links to relevant technology appraisal guidance in the section on disease-modifying pharmacological interventions.
October 2022: We added text to indicate that pulse oximetry may be less reliable in people with dark skin. We also added a link to the NHS patient safety alert on the risk of harm from inappropriate placement of pulse oximeter probes. See recommendation 1.5.1.
ISBN: 978-1-4731-0179-1